美泊利单抗对管理式医疗人群中高负担严重哮喘患者的影响

数据集获取（Figshare）

• 源站标题：Impact of mepolizumab in patients with high-burden severe asthma within a managed care population
• DOI：10.6084/m9.figshare.20341097.v2
• 发布日期：2023-03-24
• 文件数：2 个
• 文件总体积：1.71 MB
• 源站页面：https://tandf.figshare.com/articles/dataset/Impact_of_mepolizumab_in_patients_with_high-burden_severe_asthma_within_a_managed_care_population/20341097

命令行下载

curl -L -o "ijas_a_2102036_sm9232.eps" "https://ndownloader.figshare.com/files/39728262"
curl -L -o "ijas_a_2102036_sm3099.docx" "https://ndownloader.figshare.com/files/39728265"

文件清单

• ijas_a_2102036_sm9232.eps（1.57 MB）
• ijas_a_2102036_sm3099.docx（137.23 KB）

文件总体积 1.71 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

To evaluate the real-world impact of mepolizumab on the incidence of asthma exacerbations, oral corticosteroid (OCS) use and asthma exacerbation-related costs in patients with high-burden severe asthma.
This was a retrospective study of the MarketScan Commercial and Medicare Databases in patients with high-burden severe asthma (≥80th percentile of total healthcare expenditure and/or significant comorbidity burden). Patients were ≥12 years of age upon mepolizumab initiation (index date November 1, 2015–December 31, 2018) and had ≥2 mepolizumab administrations during the 6 months post-index. Asthma exacerbation frequency (primary outcome), use of OCS (secondary outcome), and asthma exacerbation-related costs (exploratory outcome) were assessed during the 12 months pre-index (baseline) and post-index (follow-up).
In total, 281 patients were analyzed. Mepolizumab significantly reduced the proportion of patients with any asthma exacerbation (P P = 0.004) in the follow-up versus baseline period. The mean number of exacerbations decreased from 2.5 to 1.5 events/patient/year (relative reduction: 40.0%; P P P P Mepolizumab reduced exacerbation frequency, OCS use and asthma exacerbation-related costs in patients with high-cost severe asthma. Mepolizumab provides real-world benefits to patients, healthcare systems and payers.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.20341097.v2（source: https://tandf.figshare.com/articles/dataset/Impact_of_mepolizumab_in_patients_with_high-burden_severe_asthma_within_a_managed_care_population/20341097）。